Esperion Therapeutics, Inc. Provides ETC-1002 Development Program Update; Reports First Quarter 2014 Financial Results
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and financial results for the first quarter ended Mar. 31, 2014.
Help employers find you! Check out all the jobs and post your resume.